Data Confirm Efficacy, Safety of Nutrafol for Menopausal Women image

Administration of Nutrafol’s Women’s Balance formulationis safe and effective in improving hair growth and quality in women going through menopausal transition, according to new data. Presented in a poster presentation at the Annual Meeting of the American Society for Dermatologic Surgery (ASDS) and reported by Nutrafol, the 6-month double-blind, randomized, placebo-controlled study is the first to specifically assess a hair supplement for menopausal women, the company says.

Nutrafol’s Women’s Balance formulation is a novel supplement bio-optimized with phytoactive ingredients to specifically address the multiple underlying factors that compromise hair growth. Use of the Nutrafol supplement resulted in statistically significant improvements compared to placebo for the number of terminal, vellus, and total hairs and shedding at day 90 with further improvement at day 180. Blinded Investigator Global Hair Assessments of both hair growth and quality showed progressive and significant improvement for Nutrafol compared with placebo, at day. Subject reported high preference for the oral supplements versus topical hair products.

“There is unfortunately a lack of research on the physical and emotional effects that menopause has on women, but we know that statistically women experience changes in hair growth and quality during this time of their lives. Shifts in hormones along with other causes generate a significant uptick in thinning hair in this population,” observes study co-author Sophia Kogan, MD, Co-founder and Chief Medical Advisor at Nutrafol. “That is why we first created Women’s Balance—the only nutraceutical clinically formulated with ingredients that specifically address root causes of thinning hair in women going through the menopausal transition. Now, after years of rigorous research and accumulation of data, we have new proof and an effective therapeutic option. 

“The results of this new randomized, double-blind, placebo-controlled study with Dr. Glynis Ablon are meaningful in that they showed a significant improvement in both objective and subjective measures including an increase in hair counts at three and six months. The study also demonstrated a significant progressive decrease in shedding for Nutrafol subjects. This was accompanied by significant visible clinical improvement in hair growth and quality, as assessed by a blinded physician investigator. To our knowledge, this is the first prospective study showing clinical efficacy of a nutraceutical supplement in improving hair growth in women with thinning hair in menopausal transition and beyond.”